Search | Clinical Trials Finder

Conditions: Obstructive Sleep Apnea
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more

Conditions: Obesity
Interventions: RGT001-075, Placebo; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more

Conditions: Obesity, Obese, Overweight or Obesity
Interventions: Bimagrumab, Semaglutide, Placebo; Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more

Conditions: Healthy Volunteer
Interventions: ABBV-295, Placebo for ABBV-295; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Obese, Weight Loss, Body Weight, Cardiometabolic Syndrome
Interventions: Exercise; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity, Overweight or Obesity
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Hollywood, Florida • Tampa, Florida • Decatur, Georgia + 2 more

Conditions: Healthy, Overweight or Obese Adults
Interventions: High Fiber bar with Inulin, Low fiber bar - no inulin; Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Healthy Volunteer
Interventions: ABBV-295, Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Obesity, Overweight, Chronic Weight Management
Interventions: Aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more

Conditions: Obesity
Interventions: Danuglipron; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psoriasis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
Interventions: PF-08653944, Acetaminophen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 25
States / cities: Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Columbus, Ohio

Conditions: Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions: Maridebart Cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Healthy
Interventions: Dabigatran etexilate (DE), Rosuvastatin, PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions: aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 74
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 67 more

Conditions: Overweight, Obesity
Interventions: Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 35,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Overweight, Obesity
Interventions: Semaglutide Nasal Spray, Placebo, Semaglutide Injection; Drug
Lead sponsor: Shanghai World Leader Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-4324, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Overweight and Obesity
Interventions: Behavioral Text Messages and Produce Box Delivery, Behavioral Text Message Program and Produce Voucher; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Overweight, Obesity
Interventions: Deaf Weight Wise 2.0; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more

Search by objective public record fields.

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Effects of Adding L-BAIBA or L-BAIBA + Grains of Paradise to Exercising Adult Overweight and Obese Men and Women

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

A Trial to Assess the Effects of Diets With and Without Inulin on Energy Expenditure in Adults.

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Weight Loss in Adults Using Semaglutide (Real-world Study)

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Study of Produce Prescription Programs in Adults With Overweight or Obesity Experiencing Nutrition Insecurity

Deaf Weight Wise 2.0: A Healthy Lifestyle Intervention With Deaf Adults Who Are Overweight or Obese

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range